Xiaofei Zhou

4.6k total citations · 1 hit paper
99 papers, 3.3k citations indexed

About

Xiaofei Zhou is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Xiaofei Zhou has authored 99 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Immunology, 36 papers in Molecular Biology and 25 papers in Oncology. Recurrent topics in Xiaofei Zhou's work include Immune Cell Function and Interaction (19 papers), Immunotherapy and Immune Responses (10 papers) and Ubiquitin and proteasome pathways (9 papers). Xiaofei Zhou is often cited by papers focused on Immune Cell Function and Interaction (19 papers), Immunotherapy and Immune Responses (10 papers) and Ubiquitin and proteasome pathways (9 papers). Xiaofei Zhou collaborates with scholars based in China, United States and South Korea. Xiaofei Zhou's co-authors include Shao‐Cong Sun, Xuhong Cheng, Yichuan Xiao, Jae‐Hoon Chang, Mikyoung Chang, Mako Nakaya, Marzenna Blonska, Xin Lin, Hongbo Hu and Jin Jin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Xiaofei Zhou

90 papers receiving 3.3k citations

Hit Papers

Inflammatory T Cell Responses Rely on Amino Acid Transpor... 2014 2026 2018 2022 2014 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaofei Zhou China 32 1.5k 1.4k 742 737 316 99 3.3k
Tao Yi China 36 1.9k 1.3× 868 0.6× 831 1.1× 673 0.9× 274 0.9× 206 4.1k
Hee Gu Lee South Korea 37 2.0k 1.4× 854 0.6× 522 0.7× 729 1.0× 454 1.4× 140 3.8k
Xiaoyun Li China 22 1.1k 0.7× 926 0.7× 526 0.7× 345 0.5× 269 0.9× 87 2.8k
Ping Wang China 37 2.2k 1.5× 1.2k 0.9× 1.0k 1.4× 806 1.1× 327 1.0× 206 4.5k
Lihua Lai China 28 1.8k 1.2× 753 0.6× 946 1.3× 374 0.5× 153 0.5× 58 3.1k
Kristopher A. Sarosiek United States 24 2.4k 1.6× 697 0.5× 594 0.8× 876 1.2× 325 1.0× 58 3.7k
M. Hinz Germany 26 1.9k 1.3× 984 0.7× 1.1k 1.5× 829 1.1× 177 0.6× 95 3.6k
Lei Zhou China 33 1.9k 1.3× 596 0.4× 1.1k 1.5× 656 0.9× 183 0.6× 110 3.3k
Yi Feng United Kingdom 33 1.8k 1.2× 834 0.6× 806 1.1× 634 0.9× 151 0.5× 91 4.2k
Zhenyue Hao Canada 20 1.6k 1.1× 1.1k 0.8× 313 0.4× 333 0.5× 250 0.8× 30 3.0k

Countries citing papers authored by Xiaofei Zhou

Since Specialization
Citations

This map shows the geographic impact of Xiaofei Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaofei Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaofei Zhou more than expected).

Fields of papers citing papers by Xiaofei Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaofei Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaofei Zhou. The network helps show where Xiaofei Zhou may publish in the future.

Co-authorship network of co-authors of Xiaofei Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaofei Zhou. A scholar is included among the top collaborators of Xiaofei Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaofei Zhou. Xiaofei Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zhou, Xiaofei, et al.. (2025). A novel multi-epitope mRNA vaccine against colorectal cancer: in silico design and immune efficacy profiling. Frontiers in Immunology. 16. 1649091–1649091.
3.
Wang, Linlin, et al.. (2023). Humanized CD36 (hCD36) mouse model supports the preclinical evaluation of therapeutic candidates targeting CD36. EXPERIMENTAL ANIMALS. 72(4). 535–545. 3 indexed citations
4.
Zhou, Xiaofei, et al.. (2023). Racial differences in time to blood pressure control of aneurysmal subarachnoid hemorrhage patients: A single-institution study. PLoS ONE. 18(2). e0279769–e0279769. 4 indexed citations
5.
Zhou, Xiaofei, et al.. (2023). 17 Humanized NKP46 mouse models for testing novel NK cell-based immunotherapies. SHILAP Revista de lepidopterología. A19–A19. 1 indexed citations
6.
Zhang, Xichen, Xuejiao Chen, Jianhua Li, et al.. (2023). Development of an LFD-RPA Assay for Rapid Detection of Pentatrichomonas hominis Infection in Dogs. Current Issues in Molecular Biology. 45(11). 9252–9261. 1 indexed citations
7.
Rodriguez, B. Leticia, Limo Chen, Yanli Li, et al.. (2023). Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance. Frontiers in Immunology. 14. 1161869–1161869. 5 indexed citations
9.
Yao, Hong-Juan, Wenping Song, Cheng Ye, et al.. (2022). An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms. Nature Communications. 13(1). 19 indexed citations
10.
Zhou, Xiaofei, Xi Tan, Xincheng Huang, et al.. (2022). The Status of Oxidative Stress in Patients with Alcohol Dependence: A Meta-Analysis. Antioxidants. 11(10). 1919–1919. 19 indexed citations
11.
Li, Shuaishuai, et al.. (2022). Electrolyte Analysis in Blood Serum by Laser-Induced Breakdown Spectroscopy Using a Portable Laser. Molecules. 27(19). 6438–6438. 7 indexed citations
12.
Hodges, Tiffany R., Collin M. Labak, Uma V. Mahajan, et al.. (2021). Impact of race on care, readmissions, and survival for patients with glioblastoma: an analysis of the National Cancer Database. Neuro-Oncology Advances. 3(1). vdab040–vdab040. 17 indexed citations
13.
Zhang, Lingyun, Chun‐Jung Ko, Yanchuan Li, et al.. (2021). Peli1 facilitates NLRP3 inflammasome activation by mediating ASC ubiquitination. Cell Reports. 37(4). 109904–109904. 43 indexed citations
14.
Li, Rui, Xiaofei Zhou, Hong-Juan Yao, & Liang Li. (2020). Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma. Journal of drug targeting. 28(9). 861–872. 13 indexed citations
15.
Zhou, Xiaofei, Jianbo Jia, Zhen Luo, et al.. (2019). Remote Induction of Cell Autophagy by 2D MoS2 Nanosheets via Perturbing Cell Surface Receptors and mTOR Pathway from Outside of Cells. ACS Applied Materials & Interfaces. 11(7). 6829–6839. 31 indexed citations
16.
Chen, Shaohua, Hui Li, L. Chen, et al.. (2016). MicroRNA-16 Modulates Melatonin-Induced Cell Growth in the Mouse-Derived Spermatogonia Cell Line GC-1 spg Cells by Targeting Ccnd1. Biology of Reproduction. 95(3). 57–57. 19 indexed citations
17.
Zou, Qiang, Jin Jin, Yichuan Xiao, et al.. (2015). T Cell Intrinsic USP15 Deficiency Promotes Excessive IFN-γ Production and an Immunosuppressive Tumor Microenvironment in MCA-Induced Fibrosarcoma. Cell Reports. 13(11). 2470–2479. 44 indexed citations
18.
Yu, Jiayi, Xiaofei Zhou, Mikyoung Chang, et al.. (2015). Regulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation. Nature Communications. 6(1). 6074–6074. 89 indexed citations
19.
Chang, Mikyoung, Wei Jin, Jae‐Hoon Chang, et al.. (2011). The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nature Immunology. 12(10). 1002–1009. 147 indexed citations
20.
Wu, Xuefeng, et al.. (2010). CARMA1 Regulation of Regulatory T Cell Development Involves Modulation of Interleukin-2 Receptor Signaling. Journal of Biological Chemistry. 285(21). 15696–15703. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026